MK-0429 (L-000845704) (Synonyms: L-000845704) |
| Catalog No.GC32055 |
MK-0429 (L-000845704) (L-000845704) est un antagoniste pan-intégrine actif par voie orale, puissant, sélectif et non peptidique avec des valeurs IC50 de 1,6 nM, 2,8 nM, 0,1 nM, 0,7 nM, 0,5 nM et 12,2 nM pour α ;vβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 227963-15-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MK-0429 is a potent integrin antagonist with IC50s of 12.2 nM (α5β1 integrin) and 2.8 nM (αvβ3 integrin), respectively.
[1]. Zhou X, et al. An integrin antagonist (MK-0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model.Pharmacol Res Perspect. 2017 Oct; 5 (5).
Average Rating: 5 (Based on Reviews and 31 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *